01 · At a glance
Quickstart Highlights
This stack pairs two synthetic research peptides — TB-500 (an actin-binding fragment of thymosin β4) and BPC-157 (a 15-amino-acid gastric-derived peptide) — supplied as two separate vials and often combined for synergistic soft-tissue repair and recovery[1][5]. Each is reconstituted and dosed independently — never mixed in one syringe. Both are unapproved research chemicals, not medicines, and no controlled human trial validates the combination — presented for research and educational use only.
Reconstitute
Reconstitute each 5 mg vial separately: 2 mL → 2.5 mg/mL (standard), or 1 mL → 5 mg/mL (advanced). Never mix the two peptides in one vial.
Daily range
TB-500 ~5 mg/week (2.5 mg, 2×/wk). BPC-157 ~500 mcg/day. Typical research cycle 4–6 weeks.
Easy measuring
On a U-100 syringe: TB-500 2.5 mg ≈ 100 units (1.0 mL); BPC-157 500 mcg ≈ 20 units (0.2 mL) at the 2.5 mg/mL dilution.
Storage
Store both reconstituted vials at 2–8 °C (35.6–46.4 °F), protected from light; do not freeze the solution. Keep the dry powder cold until use.
i
Important: Start with the Prep & Injection Guide — it covers the preparation and safety basics every protocol on this site assumes.
02 · Dosing & reconstitution
Dosing & Reconstitution Guide
Reconstitute each peptide in its own vial — never mix the two in one syringe
This stack uses two separate research-only vials — one TB-500 (5 mg) and one BPC-157 (5 mg) — each reconstituted and dosed independently. Two approaches are shown per peptide: a Standard / Gradual reconstitution (2 mL) and an Advanced / Aggressive reconstitution (1 mL). Pair every concentration with its matching recon volume. The combination is not clinically validated and these figures come from reference protocols, not approved human dosing.
TB-500 (5 mg Vial): Standard / Gradual Approach (2 mL = 2.5 mg/mL)
▪
Reconstitute: Add 2.0 mL bacteriostatic water to the TB-500 (5 mg) vial → 2.5 mg/mL. The full vial holds 5 mg.
▪
Per injection: 2.5 mg twice weekly (5 mg/week total), drawn as ~100 units (1.0 mL) on a U-100 syringe.
▪
Easy measuring: At 2.5 mg/mL, 1 mg ≈ 0.4 mL (40 units); a 2.5 mg dose reads at a full 100 units (1.0 mL).
▪
Storage: Refrigerate the reconstituted vial at 2–8 °C (35.6–46.4 °F), protected from light; do not freeze the solution.
Phase / Week(s) Dose & Frequency Volume (U-100 units / mL) Weeks 1–4 2.5 mg (2× per week) ~100 units (1.0 mL) Weekly total 5 mg/week 2 × 1.0 mL
TB-500 (5 mg Vial): Advanced / Aggressive Approach (1 mL = 5 mg/mL)
▪
Reconstitute: Add 1.0 mL bacteriostatic water to the TB-500 (5 mg) vial → 5 mg/mL.
▪
Per injection: 5 mg twice weekly (10 mg/week total), drawn as ~100 units (1.0 mL). If 5 mg in one shot feels too high, split into smaller volumes.
▪
Easy measuring: At 5 mg/mL, 1 mg ≈ 0.2 mL (20 units); a 5 mg dose reads at a full 100 units (1.0 mL).
▪
Storage: Refrigerate at 2–8 °C, protected from light; do not freeze the mixed solution.
Phase / Week(s) Dose & Frequency Volume (U-100 units / mL) Weeks 1–4 5 mg (2× per week) ~100 units (1.0 mL) Weekly total 10 mg/week 2 × 1.0 mL
BPC-157 (5 mg Vial): Standard / Gradual Approach (2 mL = 2.5 mg/mL)
▪
Reconstitute: Add 2.0 mL bacteriostatic water to the BPC-157 (5 mg) vial → 2.5 mg/mL (2,500 mcg/mL). Ideal for daily or split-daily dosing.
▪
Daily range: 500 mcg/day — either 250 mcg twice daily or 500 mcg once daily.
▪
Easy measuring: At 2,500 mcg/mL, 250 mcg ≈ 10 units (0.10 mL) and 500 mcg ≈ 20 units (0.20 mL) on a U-100 syringe.
▪
Storage: Refrigerate at 2–8 °C (35.6–46.4 °F), protected from light; do not freeze the solution.
Phase / Week(s) Daily Total & Frequency Volume (U-100 units / mL) Weeks 1–2 500 mcg/day — 250 mcg (2× daily) ~10 units (0.10 mL) Weeks 3–4 500 mcg/day — 500 mcg (1× daily) ~20 units (0.20 mL)
BPC-157 (5 mg Vial): Advanced / Aggressive Approach (1 mL = 5 mg/mL)
▪
Reconstitute: Add 1.0 mL bacteriostatic water to the BPC-157 (5 mg) vial → 5 mg/mL (5,000 mcg/mL).
▪
Daily range: Up to 750 mcg/day early (split as ~375 mcg twice daily), tapering to 500 mcg/day.
▪
Easy measuring: At 5,000 mcg/mL, 375 mcg ≈ 7.5 units (0.075 mL) and 500 mcg ≈ 10 units (0.10 mL). Below ~10 units, a 30- or 50-unit syringe improves accuracy.
▪
Storage: Refrigerate at 2–8 °C, protected from light; do not freeze the mixed solution.
Phase / Week(s) Daily Total & Frequency Volume (U-100 units / mL) Weeks 1–2 750 mcg/day — ~375 mcg (2× daily) ~7.5 units (0.075 mL) Weeks 3–4 500 mcg/day — 500 mcg (1× daily) ~10 units (0.10 mL)
Reconstitution Steps (each vial separately)
1
Draw the chosen volume of bacteriostatic water (1.0 mL or 2.0 mL) for the vial you are reconstituting into a sterile syringe.
2
Release it slowly down each vial inner wall to limit foaming. Reconstitute TB-500 and BPC-157 in their own separate vials — never combine the powders or solutions in a single vial or syringe.
3
Swirl or roll gently until fully dissolved — do not shake.
4
Label each vial with its peptide name, date and concentration, then refrigerate at 2–8 °C (35.6–46.4 °F), shielded from light.
Note
Keep TB-500 and BPC-157 in separate, clearly labelled vials and draw each into its own syringe. A typical research cycle runs about 4–6 weeks. Avoid freezing reconstituted solution, since freeze–thaw can denature the peptides.
Important: This guide is for educational purposes only and is not medical advice. For research use only. Not for human consumption.
03 · What you’ll need
Supplies Needed
Quantities below assume a research cycle of about 4–6 weeks. The stack uses two separate vials — TB-500 (5 mg) injected twice weekly and BPC-157 (5 mg) injected daily.
✓Peptide Vials — TB-500 (5 mg) + BPC-157 (5 mg)
One TB-500 (5 mg) vial covers about one week at ~5 mg/week; one BPC-157 (5 mg) vial covers ~10 days at 500 mcg/day. Buy them together as a stack.
4 weeks: ~4 TB-500 + ~3 BPC-157 6 weeks: ~6 TB-500 + ~4 BPC-157 Buy as a stack: TB-500 + BPC-157 together
✓Insulin Syringes (U-100, 1 mL)
Per injection: 1 syringe (separate vials) 4 weeks: ~36 syringes (BPC daily + TB 2×/wk) 6 weeks: ~54 syringes
✓Bacteriostatic Water (10 mL bottles)
Use 1–2 mL per 5 mg vial (2 mL = standard, 1 mL = advanced). Two vials per cycle stretch.
~4 mL per refill (2 mL × 2 vials) 4–6 week cycle: ~16–24 mL → 2–3 bottles
✓Alcohol Swabs
One for the vial stopper + one for the injection site each day.
Per injection: 2 swabs 4–6 week cycle: ~100–150 swabs → 1–2 boxes
Protocol Overview
A concise summary of this two-peptide stack, drawn from commonly cited reference protocols. Each peptide is dosed from its own vial.
▪Goal: Support soft-tissue repair, recovery and angiogenesis — TB-500 via actin-binding/cell migration and BPC-157 via preclinical tendon/gut/vascular healing. Effects are reported preclinically and the combination is not validated in humans[5][6]. ▪Schedule: TB-500 by subcutaneous injection 2× per week; BPC-157 daily (often split). Typical research cycle 4–6 weeks. ▪TB-500 dose: ~5 mg/week standard (2.5 mg, 2×/wk), up to ~10 mg/week advanced. ▪BPC-157 dose: ~500 mcg/day standard; up to ~750 mcg/day early on the advanced approach. ▪Reconstitution: 2 mL bacteriostatic water per 5 mg vial (2.5 mg/mL), or 1 mL (5 mg/mL) for the advanced approach — each vial separately. ▪Storage: Refrigerate both mixed solutions at 2–8 °C and do not freeze; keep the dry powder cold until use.
Dosing Protocol
A suggested approach for each peptide, based on common reference doses. Dose TB-500 and BPC-157 from their own separate vials.
▪TB-500: 2.5 mg twice weekly (standard, 2 mL recon) or 5 mg twice weekly (advanced, 1 mL recon). ▪BPC-157: Start ~250 mcg twice daily (500 mcg/day); some references run up to ~750 mcg/day early before settling at 500 mcg/day. ▪Cycle length: Typically 4–6 weeks, extended only as research goals require. ▪Separate vials: Always inject each peptide from its own vial and syringe — never combine TB-500 and BPC-157 in a single syringe. ▪Timing: Inject at consistent times and rotate injection sites systematically.
Storage Instructions
Correct storage preserves the stability and activity of both peptides.
▪Lyophilized: Hold the dry vial at −20 °C (−4 °F) in dry, dark conditions and limit moisture exposure[7]. ▪Reconstituted: Refrigerate at 2–8 °C (35.6–46.4 °F) and use within about 28 days; do not freeze the mixed solution, as freezing can denature peptides[8]. ▪Handling: Let frozen vials warm to room temperature before opening so condensation won’t form, and keep the solution clear of heat and direct light. ▪Freeze–thaw: Avoid repeated freeze–thaw cycles of the reconstituted solution.
04 · Good to know
Important Notes
Practical points that keep daily administration safe and consistent.
▪Sterile technique: Use a fresh sterile U-100 insulin syringe each time and drop it straight into a puncture-proof sharps container afterward. ▪Site rotation: Move between abdomen, thighs and upper arms to reduce local irritation and lipohypertrophy[9]. ▪Slow injection: Push the plunger slowly and pause a few seconds before withdrawing the needle to prevent backflow. ▪Separate vials: Keep TB-500 and BPC-157 in their own clearly labelled vials, draw each into its own syringe, and never mix them in one syringe. Log doses and sites to keep the protocol consistent. ▪Regulatory note: Neither peptide is FDA-approved; both are unapproved research chemicals. TB-500 remains a 503A Category-2 bulk substance, while BPC-157 was removed from the 503A list in April 2026 and is under PCAC review. Both are prohibited by WADA (Class S2) for athletic use, and TB-500 is detectable in doping control[10].
05 · How it works
How This Works
TB-500 is a synthetic peptide that reproduces the active actin-binding region of Thymosin Beta-4 (Tβ4) — the short sequence Ac-LKKTETQ[1][2]. By sequestering G-actin it helps regulate actin polymerization, the process behind cell migration in wound healing; preclinical work also links it to angiogenesis, stem/progenitor-cell recruitment, and reduced inflammation and fibrosis[5][6].
BPC-157 is a synthetic 15-amino-acid peptide derived from a protective protein found in gastric juice. In animal models it has been associated with tendon, ligament, muscle and gut healing, angiogenesis and cytoprotection — effects reported preclinically, not confirmed in controlled human trials.
The two are stacked on the rationale that TB-500 acts more systemically (cell migration, vascular repair) while BPC-157 is thought to act on localized connective-tissue and gut healing — a proposed “synergistic recovery” combination. This synergy is a hypothesis only.
Important caveat: there is no completed controlled human trial validating the TB-500 + BPC-157 combination, and the limited human data on each peptide individually are minimal. Recovery and healing claims rest on animal data and anecdote and should be read as hypotheses.
Both peptides are not approved medicines. They are unapproved research chemicals presented here for research and educational purposes only.
06 · Daily habits
Lifestyle Factors
Habits that may support recovery alongside the protocol.
▪Nutrition: Keep protein intake adequate to give tissue repair the building blocks it needs. ▪Activity & rest: Pair appropriate movement with real recovery time and avoid overtraining during an injury-recovery phase. ▪Sleep: Aim for 7–9 hours to support the body’s natural repair processes. ▪Stress: Manage stress with evidence-based practices, since it influences overall healing.
07 · What to expect
Potential Benefits & Side Effects
What preclinical literature describes for each peptide; human evidence is limited, the combination is unstudied, and individual results vary.
Potential Benefits
▪Soft-tissue repair (preclinical): Animal studies report faster wound healing via TB-500-driven angiogenesis and cell migration, plus BPC-157-associated tendon, ligament and gut healing[5][6]. ▪Inflammation & vascular support (preclinical): Both peptides have been linked to reduced inflammation and improved angiogenesis in animal models[11]. ▪Tolerability (preclinical): Each peptide is generally well tolerated in animal studies, with occasional mild injection-site reactions. ▪Note on humans: These benefits are not established in humans, and no controlled human trial validates the TB-500 + BPC-157 combination[13].
Common Side Effects
▪Injection-site reactions: Mild redness, tenderness or soreness can occur; rotating sites helps. ▪Unknown long-term profile: Human safety data is limited, so caution and monitoring are advised. ▪Sport restriction: Both TB-500 and BPC-157 are WADA-prohibited (Class S2) for athletes; TB-500 is detectable in testing.
08 · Injection technique
Injection Technique
Because this is a two-vial stack, draw and inject TB-500 and BPC-157 separately — never mix them in one syringe. General subcutaneous technique follows established clinical best-practice guidance[14][15].
Pre-Injection Preparation
▪Wash your hands well with soap and water. ▪Wipe the vial stopper with an alcohol swab and let it air-dry. ▪Choose a site (abdomen, thigh, or upper arm) and clean it with a fresh alcohol swab, letting it dry fully[15]. ▪Draw the intended dose, then check for air bubbles and push any out.
Injection Procedure
▪Pinch a skinfold at the chosen site between thumb and forefinger. ▪Insert the needle into the pinch at a 45–90-degree angle (use 45 degrees if the fat layer is thin)[14]. ▪Skip aspiration for subcutaneous shots — it isn’t needed[14]. ▪Press the plunger slowly and steadily until it’s fully down. ▪Wait 5–10 seconds, then pull the needle straight out to prevent leakage.
Post-Injection Care
▪Drop the used syringe straight into a puncture-proof sharps container — never recap a needle. ▪Return the reconstituted vial to the fridge right away. ▪Rotate the injection site each day to prevent irritation and lipohypertrophy[9]. ▪Watch the site for excess redness, swelling, or signs of infection.
09 · Where to source
Recommended Source
For high-purity research peptides, we point researchers to Prime Lab Peptides for the TB-500 (5 mg) + BPC-157 (5 mg) stack — supplied as two separate vials.
Why Prime Lab Peptides?
▪Top-rated on Trustpilot: Independently reviewed as the highest-rated peptide lab on Trustpilot — making it the best current source in the USA. ▪Third-party tested: Every batch ships with a Certificate of Analysis (COA) confirming purity and composition. ▪Consistent quality: ISO-aligned manufacturing and handling keep product integrity reliable batch to batch. ▪Cold-chain integrity: Temperature-controlled shipping and storage across the whole fulfilment chain. ▪Research-grade purity: Fit for educational and research use that demands high-quality peptides.
Note: Product availability and specifications subject to change. Verify current product details on supplier website.
Shop the TB-500 + BPC-157 Stack →
10 · The evidence
References
1
FASEB Journal
Biological activities of thymosin beta-4 mapped to active peptide sequences, including the fragment marketed as TB-500.
View Source ↗ 2
Journal of Chromatography A (PubMed)
Doping-control analysis of TB-500 as a synthetic thymosin beta-4 fragment in biological samples.
View Source ↗ 3
WADA Scientific Research
Investigation of TB-500 metabolism, synthesis of its metabolites, and detection limits.
View Source ↗ 4
Racing Medication & Testing Consortium
Thymosin beta-4 regulatory bulletin covering TB-500 use in equine sports medicine.
View Source ↗ 5
Journal of Investigative Dermatology (PubMed)
Thymosin beta-4 accelerates wound healing in a preclinical model.
View Source ↗ 6
FASEB Journal (PubMed)
Active-site mapping of thymosin beta-4 fragments for angiogenesis and cell migration.
View Source ↗ 7
Peptide Storage Guide
Best practices for storing lyophilized peptides (temperature, humidity and light protection).
View Source ↗ 8
Bacteriostatic Water Guidance
Bacteriostatic water for injection: multi-dose vial stability and handling.
View Source ↗ 9
NCBI Bookshelf
Best practices for subcutaneous injection: aseptic technique and site rotation.
View Source ↗ 10
WADA Prohibited List
Classification of TB-500 as a prohibited substance in competitive sport.
View Source ↗ 11
Journal of Investigative Dermatology
Thymosin beta-4 wound-healing mechanisms: collagen deposition, angiogenesis and granulation tissue.
View Source ↗ 12
Journal of Chromatography B (PubMed)
Quantification of TB-500 metabolites and screening of wound-healing activity (prodrug hypothesis).
View Source ↗ 13
ClinicalTrials.gov
Trial registry for full-length thymosin beta-4 (e.g., dermal and ocular indications); no completed efficacy trials of the TB-500 fragment.
View Source ↗ 14
Centers for Disease Control and Prevention (CDC)
Subcutaneous injection technique: angle, site and no-aspiration guidance.
View Source ↗ 15
Subcutaneous Injection Technique (Patient Education)
How to administer a subcutaneous injection: clinical technique guidelines.
View Source ↗ 17
Journal of Applied Physiology / PubMed
BPC-157 preclinical tendon, ligament and muscle healing and angiogenesis in animal models.
View Source ↗ 18
PubMed
BPC-157 cytoprotection and gut-healing studies; gastric-derived pentadecapeptide pharmacology.
View Source ↗ 16
Prime Lab Peptides
TB-500 (5 mg) + BPC-157 (5 mg) stack product page — purity specifications and certificates of analysis.
View Source ↗